Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 545 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HIV in Adults Clear all
Completed No phase listed Observational

IMPAACT 2015 - Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults With Cognitive Impairment

NCT03416790
View directory record Official record
Conditions
HIV-1-infection
Interventions
Not listed
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
13 Years to 24 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs

NCT00920088
View directory record Official record
Conditions
Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions
darunavir/ritonavir, lopinavir/ritonavir, Midazolam, Dextromethorphan, Flurbiprofen, GSK2248761
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2010 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

NCT00376090
View directory record Official record
Conditions
HIV Infections
Interventions
MVA-CMDR, Placebo
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

NCT00822120
View directory record Official record
Conditions
Lymphoma, Nonneoplastic Condition
Interventions
bleomycin sulfate, filgrastim, ABVD regimen, BEACOPP regimen, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, prednisone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 60 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
423
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 290 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

NCT05144386
View directory record Official record
Conditions
HIV-1-infection
Interventions
EBT-101
Biological
Lead sponsor
Excision BioTherapeutics
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
San Francisco, California • St Louis, Missouri • Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Many Men, Many Voices, An STD/HIV Prevention Intervention for Black MSM

NCT00137631
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Many Men, Many Voices (3MV)
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older · Male only
Enrollment
341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2010 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults

NCT00083603
View directory record Official record
Conditions
HIV Infections
Interventions
rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT), rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT), Empty TBC-FPV, TBC-MVA and TBC-FPV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
4
States / cities
Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

NCT03110380
View directory record Official record
Conditions
HIV-1-infection
Interventions
B/F/TAF, F/TAF, DTG, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
66
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 11, 2026, 5:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir

NCT00273273
View directory record Official record
Conditions
HIV Infections
Interventions
blood draw
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults

NCT00111605
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 gag DNA, HIV-1 gag DNA plus IL-12 DNA adjuvant, CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine), Sodium chloride injection (0.9%)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2008
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults

NCT00002427
View directory record Official record
Conditions
HIV Infections
Interventions
Hydroxyurea, Stavudine, Didanosine
Drug
Lead sponsor
Research Institute for Genetic and Human Therapy
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stamford, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

NCT02831764
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Results available

B/F/TAF Switch Study for HIV-HBV Coinfection

NCT03797014
View directory record Official record
Conditions
HIV-1-infection, Hepatitis B
Interventions
B/F/TAF
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Not applicable Interventional

Juvenile Justice Girls Randomized Control Trial: Young Adult Follow-up

NCT01341626
View directory record Official record
Conditions
Delinquency, Drug Use
Interventions
Treatment Foster Care (TFCO), Group Care
Behavioral
Lead sponsor
Oregon Social Learning Center
Other
Eligibility
13 Years to 18 Years · Female only
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2016
U.S. locations
2
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Development of a New HIV Vaccine

NCT00051922
View directory record Official record
Conditions
HIV Infections
Interventions
PolyEnv1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 32 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)

NCT02652546
View directory record Official record
Conditions
HIV, Inflammation
Interventions
Assess Safety, Effect of drug on viral load, Effect of drug on T-cell count, Effect of drug on inflammatory biomarkers
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma

NCT00392990
View directory record Official record
Conditions
Lymphoma
Interventions
Regimen A, Regimen B
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
8
States / cities
Chicago, Illinois • Maywood, Illinois • Park Ridge, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults

NCT00249106
View directory record Official record
Conditions
HIV Infection
Interventions
ADVAX
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
2
States / cities
New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Not applicable Interventional

Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected Adults

NCT00099684
View directory record Official record
Conditions
HIV Infections
Interventions
Ezetimibe
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults

NCT00097838
View directory record Official record
Conditions
HIV Infections
Interventions
AVX101, placebo
Biological · Other
Lead sponsor
AlphaVax, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults

NCT03721510
View directory record Official record
Conditions
HIV/AIDS
Interventions
PGT121 + VRC07-523LS, PGT121 + VRC07-523LS + PGDM1400
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
3
States / cities
Orlando, Florida • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Trial of SystemCHANGE to Improve Exercise, Diet and Health in HIV-Infected Adults

NCT02553291
View directory record Official record
Conditions
HIV, Cardiovascular Disease
Interventions
SystemCHANGE, Control
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection

NCT02175680
View directory record Official record
Conditions
HIV, Human Immunodeficiency Virus
Interventions
PRO 140, Historical data
Drug · Other
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 11, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects

NCT02064374
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Metformin 500 mg q12h, Dolutegravir 50 mg q24h, Dolutegravir 50 mg q12h
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 11, 2026, 5:49 AM EDT